Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3135519 | 0.90 | EGLN3 (0.54) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2903353 | 0.86 | ALDH1A1 (0.51) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2915918 | 0.86 | EGLN3 (0.50) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2901643 | 0.84 | KDM4E (0.59) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2902808 | 0.84 | EGLN3 (0.50) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2901279 | 0.83 | EGLN3 (0.52) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2901678 | 0.83 | EGLN3 (0.48) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2912072 | 0.83 | EGLN3 (0.52) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2894346 | 0.83 | EGLN3 (0.72) | SMN1; SMN2ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL2903017 | 0.82 | EGLN3 (0.47) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2240178-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | KDM4E 206/4885SMN1; SMN2 4048/4885ALDH1A1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.